Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LyRICX first-line treatment trial in advanced esophagogastric cancer
NL-OMON59284Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan, carboplatin, oxaliplatin, nivolumab, capecitabine and 2 more in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Progression-free survival 1 and Neurotoxicity. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON59284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59284.